Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Open
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by whisky11on Apr 21, 2021 12:35pm
178 Views
Post# 33037587

RE:RE:RE:RE:Open

RE:RE:RE:RE:OpenRaiders11]How many times do I have to post this,I have a measly 215,000 shares at 4 cents,100 thousand warrants at .015 cents,I don't want buyers at .045 cents or less I want buyers that are buying into the bid! IT IS the MANIPULATORS that stack the ask side to get it down to their low bids,been trading stocks for over 50 years whiskey,us little guys are just ponzies in the markets.


whisky11: I am a queen of England we are not impressed with your explanation.
We have 20 trillion shares of Claritas, see you can type what you
want ,your auction says more than what you saying about yourself.
If you go to jail and ask any convict over there if his conviction was justified, everyone would say no I'm a virgin, innocent ,nave person.(Bullshit)
You're spreading negativity, this is only  $80,000 in money value trade off whole day.
Anyways I'm happy from this outcome, I'm waiting for money, just sold a nice piece of land in muskoka.
Keep the price down please.
Pledge to the management, keep doing a good job.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities